Home › Urothelial (Transitional Cell) Carcinoma › California › Orange
Pag-aaral pangklinika para sa Urothelial (Transitional Cell) Carcinoma sa Orange, CA
Isang pag-aaral para sa Urothelial (Transitional Cell) Carcinoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Orange. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Nagre-recruitPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Nagre-recruitPhase 1/2
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Nagre-recruitPhase 1/2
- UC Irvine Health, Orange
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Nagre-recruitPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Nagre-recruitPhase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Nagre-recruitPhase 3
- UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Nagre-recruitMaagang Phase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Nagre-recruitPhase 2
- UC Irvine Health, Orange
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Nagre-recruitPhase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Orange
Pag-aaral para sa Urothelial (Transitional Cell) Carcinoma sa ibang lungsod
- Nashville, TN23 pag-aaral
- New York City, NY22 pag-aaral
- Houston, TX19 pag-aaral
- Dallas, TX18 pag-aaral
- Edison, NJ18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Queens, NY15 pag-aaral
- Chicago, IL14 pag-aaral
- Arlington, VA12 pag-aaral
- Boston, MA11 pag-aaral
- San Antonio, TX11 pag-aaral
- Austin, TX10 pag-aaral
Iba pang pag-aaral sa Orange
- Non-Small Cell Lung Cancer25 pag-aaral
- Metastatic Cancer20 pag-aaral
- Colorectal Cancer16 pag-aaral
- Kanser sa Ovary16 pag-aaral
- Kanser sa Pancreas15 pag-aaral
- Melanoma14 pag-aaral
- Kanser sa Atay (Hepatocellular Carcinoma)14 pag-aaral
- Kanser sa Suso14 pag-aaral
- Kanser sa Baga14 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Tiyan13 pag-aaral
- Kanser (lahat ng uri)13 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.